Risk Factors and Symptoms of Meibomian Gland Loss in a Healthy Population
Table 2
Associations of systemic factors with meibomian gland loss (MGL) in 182 eyes of healthy volunteers.
Parameters
MGL (%)
Abnormal meiboscore (stage ≥ 2)
Yes
No
OR (95% CI)#
#
Diabetes mellitus
41.9 ± 15.8
28.9 ± 11.4
2,82 (0,83–9,63)
0,096
Heart disease
34.5 ± 16.4
29.4 ± 11.5
1,15 (0,41–3,2)
0,79
Thyroid disease
35.1 ± 10.9
29.3 ± 12.2
2.04 (0.76–5.51)
0.16
Medications:
(i) Antihypertensive drugs
32.6 ± 14.4
29.4 ± 11.7
1.44 (0.59–3.52)
0.42
(ii) Hormone replacement therapy+
38.3 ± 10.6
28.4 ± 11.5
5.72 (1.8–18.13)
0.003
(iii) Anticontraceptive drugs+
2,46 (0,62–9,76)
0,197
(iv)
43.9 ± 21.8
29.2 ± 11.8
2.74 (0.2–36.82)
0.44
(v) Antidepressants
26.7 ± 10.1
30.1 ± 12.3
1,16 (0,24–5,49)
0,85
(vi) Antiallergic drugs
39.4 ± 12.9
28.4 ± 11.4
6.19 (2.39–16.05)
0.0002
Smoking
34.3 ± 15.4
28.4 ± 10.5
2.05 (1.01–4.14)
0.04
Computer use
28.3 ± 12.1
33.0 ± 12.0
0.8 (0.35–1.81)
0.59
Work environment:
(i) Outdoors
27.8 ± 10.7
30.2 ± 12.4
0,58 (0,19–1,73)
0,32
(ii) Indoors with air conditioning
29.6 ± 11.1
30.1 ± 12.6
1,59 (0,78–3,24)
0,2
(iii) Indoors without air conditioning
29.9 ± 12.2
30.1 ± 12.4
0,97 (0,46–2,05)
0,94
logistic regression model adjusted for age and sex with the specified parameter as the independent variable and abnormal meiboscore as dependent variable. +In the subgroup of women. the subgroup of men.
